Last updated: April 2, 2026
What is the Drug Associated with NDC 23155-0889?
NDC 23155-0889 corresponds to Zynlonta (loncastuximab tesirine-lpyl), a CD19-targeted antibody-drug conjugate approved by the FDA in April 2021. It is indicated for relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.
Market Landscape for Zynlonta
Key Competitors
| Product Name |
Mechanism |
Approvals / Indications |
Market Share (Estimated) |
Price Range (USD) per dose |
| Rituximab (Rituxan) |
CD20 monoclonal antibody |
Multiple B-cell malignancies |
40-50% |
$4,000 - $7,000 |
| Polatuzumab vedotin |
CD79b-directed ADC |
Relapsed diffuse large B-cell lymphoma (DLBCL) |
10-15% |
$18,000 - $25,000 |
| Tafasitamab + Lenalidomide |
CD19 target + immunomodulator |
Relapsed/refractory DLBCL |
10% |
Combination therapy approx. $10,000/month |
Market Potential
The B-cell lymphoma treatment market is projected to grow due to increasing incidence rates. The global non-Hodgkin lymphoma (NHL) market size was approximately $9.8 billion in 2022 and expected to grow at a CAGR of 6% through 2030.
Epidemiology
- US incidence (2022): ~77,000 cases of DLBCL.
- Relapsed/refractory cases: Estimated 25-30% of diagnosed cases.
- Treatment landscape: Involves monoclonal antibodies, BTK inhibitors, chemotherapy, and ADCs like Zynlonta.
Price and Cost Analysis
Current Price Points
- Zynlonta: Approx. $37,000 - $40,000 per 20 mg vial, administered once every 3 weeks for up to 2 years.
- Compared to competitors: Rituximab (approx. $4,000-$7,000 per dose), Polatuzumab (approx. $20,000-$25,000 per cycle).
Pricing Strategy Factors
- Orphan drug designation: May provide pricing leverage.
- Competitive landscape: High-price positioning similar to Polatuzumab.
- Cost of goods: Antibody-drug conjugate production remains costly, influencing retail price.
Reimbursement Considerations
- Reimbursement rates vary based on coverage policies.
- Payer negotiations favor high-cost drugs with demonstrated improved outcomes.
Projected Market Penetration and Revenue
| Year |
Estimated Units Sold |
Revenue (USD millions) |
Assumptions |
| 2023 |
2,000 |
$75 |
Launch year, initial uptake |
| 2024 |
4,500 |
$170 |
Market expansion, increased clinician familiarity |
| 2025 |
7,000 |
$266 |
Broader adoption in relapsed/refractory settings |
| 2026 |
10,000 |
$370 |
Increased treatment lines, pricing adjustments |
Assumption: The average price per treatment course remains at approximately $37,000 but could increase with inflation or specific payer negotiations.
Pricing Trend Predictions
- Short term (1-2 years): Pricing remains stable due to manufacturing costs and competitive positioning.
- Mid-term (3-5 years): Potential for price adjustments downward or upward depending on clinical outcomes, value-based pricing, and usage expansion.
- Long-term (beyond 5 years): Entry of biosimilars or generics would pressure prices; currently, no biosimilar options exist for ADCs like Zynlonta.
Regulatory and Reimbursement Outlook
- FDA approval for additional indications: Could expand market size and justify price increases.
- Coverage policies: Favorable reimbursement depends on demonstrated cost-effectiveness, especially relative to existing therapies.
Summary
Zynlonta (loncastuximab tesirine-lpyl) presents a high-price, targeted therapy for relapsed or refractory LBCL within a growing lymphoma market. Its initial pricing aligns with other ADCs, but market penetration faces competition from established monoclonal antibodies and emerging treatments. Market growth depends on clinical outcomes, reimbursement policies, and potential indication expansions.
Key Takeaways
- The drug's current price ranges around $37,000 per treatment cycle.
- The treatment landscape is competitive but valuations are $20,000+ for similar ADCs.
- Market penetration is projected to grow steadily, with revenues potentially reaching several hundred million dollars annually by 2026.
- Long-term price stability will depend on clinical efficacy, payer negotiations, and possible biosimilar entry.
FAQs
1. What therapeutic advantages does Zynlonta have over existing B-cell lymphoma treatments?
It offers targeted delivery of cytotoxic agents directly to CD19-expressing cells, potentially improving efficacy in relapsed/refractory cases where other therapies fail.
2. How does its pricing compare to other ADCs?
It aligns with high-cost ADCs like Polatuzumab vedotin (~$20,000 - $25,000 per cycle), but is higher than traditional monoclonal antibodies like Rituximab ($4,000 - $7,000).
3. What factors could influence its future price?
Market competition, clinical trial results, approval of expanding indications, and emergence of biosimilars.
4. What is the potential for geographic market expansion?
Regulatory approval in Europe and Asia could significantly increase overall revenue, depending on local pricing and reimbursement policies.
5. How might patient access be affected?
Coverage policies, manufacturer assistance programs, and overall cost-effectiveness will determine patient access levels.
References
- Food and Drug Administration. (2021). FDA approves loncastuximab tesirine-lpyl for large B-cell lymphoma. FDA.
- MarketWatch. (2022). Global Non-Hodgkin Lymphoma Market Size, Trends & Forecasts.
- IQVIA. (2022). Oncology market reports.
- Evaluate Pharma. (2022). Oncology market price and sales estimates.
- Centers for Disease Control and Prevention. (2022). Cancer Statistics.
